Loading cancer entity…
Loading cancer entity…
Clinical trials
13 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07050186 | Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma | recruiting | Phase 2 | 15 | Northwestern UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05019716 | Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma | recruiting | Phase 1 / Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 |
| clinicaltrials |
| NCT05372640 | Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07459127 | Multicenter Retrospective Cohort of Pulmonary NUT Carcinoma | active not recruiting | — | 150 | Three Gorges Hospital of Chongqing UniversityOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05812027 | A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors | active not recruiting | — | 1,150 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05265429 | Biology of Young Lung Cancer Study: The YOUNG LUNG Study | recruiting | — | 500 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT07072143 | An International Study on Pediatric Patients With Rare Tumors.(PARTNER) | recruiting | — | 6,250 | Azienda Ospedaliera di PadovaOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT05488548 | Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 75 | Epigenetix, Inc.INDUSTRY | 1 | Jan 14, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Aug 18, 2026source: clinicaltrials